Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Kaser

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|October 14, 2020
Genetic Risk of Severe Covid-19Arthur Kaser
Drug Research|November 17, 2021
Metabolism - New Therapeutic Targets for Inflammatory Bowel DiseaseArthur Kaser
Best Practice & Research. Clinical Gastroenterology|June 11, 2014
Not all monoclonals are created equal - lessons from failed drug trials in Crohn's diseaseArthur Kaser
Expert Opinion on Therapeutic Targets|April 16, 2008
Novel therapeutic targets in the treatment of IBDArthur Kaser, Herbert Tilg
Expert Opinion on Biological Therapy|October 22, 2002
Antitumour necrosis factor therapy in Crohn's diseaseHerbert Tilg, Arthur Kaser
Expert Opinion on Biological Therapy|April 23, 2004
Type I interferons and their therapeutic role in Th2-regulated inflammatory disordersHerbert Tilg, Arthur Kaser
The Journal of Clinical Investigation|June 3, 2011
Gut microbiome, obesity, and metabolic dysfunctionHerbert Tilg, Arthur Kaser
Current Drug Delivery|October 26, 2011
"Metabolic aspects" in inflammatory bowel diseasesArthur Kaser, Herbert Tilg
Gut|June 13, 2012
Seventeen in Crohn's disease: less prime than we thought?Tim Raine, Arthur Kaser
Current Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's diseaseHerbert Tilg, Arthur Kaser
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|October 14, 2020
Genetic Risk of Severe Covid-19Arthur Kaser
Drug Research|November 17, 2021
Metabolism - New Therapeutic Targets for Inflammatory Bowel DiseaseArthur Kaser
Best Practice & Research. Clinical Gastroenterology|June 11, 2014
Not all monoclonals are created equal - lessons from failed drug trials in Crohn's diseaseArthur Kaser
Expert Opinion on Therapeutic Targets|April 16, 2008
Novel therapeutic targets in the treatment of IBDArthur Kaser, Herbert Tilg
Expert Opinion on Biological Therapy|October 22, 2002
Antitumour necrosis factor therapy in Crohn's diseaseHerbert Tilg, Arthur Kaser
Expert Opinion on Biological Therapy|April 23, 2004
Type I interferons and their therapeutic role in Th2-regulated inflammatory disordersHerbert Tilg, Arthur Kaser
The Journal of Clinical Investigation|June 3, 2011
Gut microbiome, obesity, and metabolic dysfunctionHerbert Tilg, Arthur Kaser
Current Drug Delivery|October 26, 2011
"Metabolic aspects" in inflammatory bowel diseasesArthur Kaser, Herbert Tilg
Gut|June 13, 2012
Seventeen in Crohn's disease: less prime than we thought?Tim Raine, Arthur Kaser
Current Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's diseaseHerbert Tilg, Arthur Kaser
Pageof 18